{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:52Z","timestamp":1790774452981,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012058","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T00:00:00Z","timestamp":1540944000000}}],"reference-count":87,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012058.pub2","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T19:16:29Z","timestamp":1541013389000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Gene therapy for peripheral arterial disease"],"prefix":"10.1002","volume":"2018","author":[{"given":"Rachel","family":"Forster","sequence":"first","affiliation":[{"name":"University of Edinburgh; Usher Institute of Population Health Sciences and Informatics; Edinburgh UK EH8 9AG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Liew","sequence":"additional","affiliation":[{"name":"Newcastle University; Institute of Cellular Medicine; 4th Floor, William Leech Building Framlington Place Newcastle upon Tyne UK NE2 4HH"},{"name":"National University of Ireland Galway (NUIG), Portiuncula University Hospital & Galway University Hospital, Saolta University Health Care Group; Galway Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vish","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital; Department of General and Vascular Surgery; Queen Elizabeth Avenue Sheriff Hill Gateshead Tyne and Wear UK NE9 6SX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Shaw","sequence":"additional","affiliation":[{"name":"Newcastle University; Institute of Cellular Medicine; 4th Floor, William Leech Building Framlington Place Newcastle upon Tyne UK NE2 4HH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Stansby","sequence":"additional","affiliation":[{"name":"Freeman Hospital; Northern Vascular Centre; Newcastle upon Tyne UK NE7 7DN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"issue":"9781","key":"10.1002\/14651858.CD012058.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0002|cit2","first-page":"209","article-title":"Result of phase III TAMARIS trial","volume":"16","author":"Hiatt","year":"2014","journal-title":"Journal of Gene Medicine"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0003|cit3","unstructured":"NCT00566657 Efficacy and safety of XRP0038\/NV1FGF in critical limb ischemia patients with skin lesions (TAMARIS) clinicaltrials.gov\/ct2\/show\/NCT00566657"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Van Belle E Nikol S Norgren L Baumgartner I Driver V Hiatt W A randomized, double-blind placebo-controlled study of NV1FGF gene therapy in critical limb ischemia patients (TAMARIS Study). Rationale, design and baseline patient characteristics Archives of Cardiovascular Diseases Supplements 2011 77 8","DOI":"10.1016\/S1878-6480(11)70240-3"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejvs.2011.04.030","article-title":"Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia","volume":"42","author":"Belle","year":"2011","journal-title":"European Journal of Vascular & Endovascular Surgery"},{"issue":"16","key":"10.1002\/14651858.CD012058.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/CIRCULATIONAHA.110.009407","article-title":"Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication","volume":"124","author":"Creager","year":"2011","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0007|cit7","unstructured":"NCT00117650 Safety and efficacy study of Ad2\/Hypoxia inducible factor (HIF)-1a\/VP16 gene transfer in patients with intermittent claudication (WALK) clinicaltrials.gov\/ct2\/show\/NCT00117650"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012058.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1525-0016(16)33791-1","article-title":"Long-term results of PCMV-VEGF165 intramuscular gene transfer in patients with chronic lower limb ischemia","volume":"23","author":"Bozo","year":"2015","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1074248415574336","article-title":"PCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia","volume":"20","author":"Deev","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD012058.pub2-BIB0010|cit10","first-page":"38","article-title":"Efficacy of using VEGF165 gene in comprehensive treatment of patients with stage 2A-3 lower limb chronic ischaemia","volume":"20","author":"Deev","year":"2014","journal-title":"Angiologiia i Sosudistaia Khirurgiia"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0011|cit11","unstructured":"NCT03068585 Efficiency, safety and portability of neovasculgen clinicaltrials.gov\/ct2\/show\/NCT03068585"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40256-016-0210-3","article-title":"Results of an international postmarketing surveillance study of pl-VEGF165 safety and efficacy in 210 patients with peripheral arterial disease","volume":"17","author":"Deev","year":"2017","journal-title":"American Journal of Cardiovascular Drugs"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD012058.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/j.jvs.2016.03.223","article-title":"Four-year results of an international, multicenter, randomized clinical trial of a pCMV-vegf165 in progressive ischemia caused by atherosclerotic peripheral arterial disease: results from 332 participants","volume":"63","author":"Plaksa","year":"2016","journal-title":"Journal of Vascular Surgery"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ahj.2007.01.038","article-title":"Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease","volume":"153","author":"Grossman","year":"2007","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0015|cit15","unstructured":"NCT00068133 A phase II multicenter, double-blind, placebo-controlled, trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease clinicaltrials.gov\/show\/NCT00068133"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/104303404323142060","article-title":"Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease","volume":"15","author":"Rajagopalan","year":"2004","journal-title":"Human Gene Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012058.pub2-BIB0017|cit17","first-page":"P1497","article-title":"Dose and regimen effects of intramuscular NV1FGF in patients with critical limb ischemia: a randomized, double-blind, placebo controlled study","volume":"27","author":"Henry","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0018|cit18","unstructured":"NCT00798005 Efficacy and safety study of NV1FGF in patients with severe peripheral artery occlusive disease. (TALISMAN202) clinicaltrials.gov\/ct2\/show\/NCT00798005"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/gt.2011.85","article-title":"Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease","volume":"19","author":"Niebuhr","year":"2012","journal-title":"Gene Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"A19419","DOI":"10.1161\/circ.130.suppl_2.19419","article-title":"A phase IIA randomized double-blind, placebo controlled study to evaluate plasmid stromal cell-derived factor-1 for treatment of critical limb ischemia - the STOP-CLI trial","volume":"130","author":"Kibbe","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/gt.2015.110","article-title":"Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia","volume":"23","author":"Kibbe","year":"2016","journal-title":"Gene Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0022|cit22","unstructured":"NCT01064440 Safety and efficacy study using gene therapy for critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT01064440"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Perin ECM A phase 2, double-blind, randomized, placebo-controlled, multicenter trial of the safety and efficacy of plasmid DNA expressing 2 isoforms of hepatocyte growth factor in patients with critical limb ischemia Journal of the American College of Cardiology 2014 A2092","DOI":"10.1016\/S0735-1097(14)62095-7"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/hum.2006.17.683","article-title":"Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial","volume":"17","author":"Kusumanto","year":"2006","journal-title":"Human Gene Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012058.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"Makinen","year":"2002","journal-title":"Molecular Therapy"},{"issue":"4","key":"10.1002\/14651858.CD012058.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2011.109","article-title":"10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb","volume":"19","author":"Muona","year":"2012","journal-title":"Gene Therapy"},{"issue":"1","key":"10.1002\/14651858.CD012058.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1191\/1358863x03vm460oa","article-title":"Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial","volume":"8","author":"Mohler","year":"2003","journal-title":"Vascular Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0002-9149(02)02524-9","article-title":"Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication","volume":"90","author":"Rajagopalan","year":"2002","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0029|cit29","unstructured":"NCT00368797 Efficacy and safety study of NV1FGF in patients with severe peripheral artery occlusive disease clinicaltrials.gov\/ct2\/show\/NCT00368797"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/gt.2011.85","article-title":"Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease","volume":"19","author":"Niebuhr","year":"2012","journal-title":"Gene Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Molecular Therapy"},{"issue":"9-10","key":"10.1002\/14651858.CD012058.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jgm.2806","article-title":"Angiogenic gene therapy does not cause retinal pathology","volume":"16","author":"Prokosch","year":"2014","journal-title":"Journal of Gene Medicine"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0033|cit33","unstructured":"NCT00060892 Study of HGF via plasmid vector to improve perfusion in critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT00060892"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1191\/1358863x04vm557oa","article-title":"Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial","volume":"9","author":"Powell","year":"2004","journal-title":"Vascular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012058.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","article-title":"Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia","volume":"118","author":"Powell","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0036|cit36","unstructured":"NCT00189540 Study of hepatocyte growth factor (HGF) via plasmid vector to improve perfusion in critical limb ischemia patients with peripheral ischemic ulcers clinicaltrials.gov\/ct2\/show\/NCT00189540"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","article-title":"Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial","volume":"52","author":"Powell","year":"2010","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0038|cit38","doi-asserted-by":"crossref","unstructured":"Powell RJ Marrot P Annex BH Safety and efficacy of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial Journal of Vascular Surgery 2009 451","DOI":"10.1016\/j.jvs.2010.07.044"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0002-8703(03)00102-9","article-title":"Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial","volume":"145","author":"Rajagopalan","year":"2003","journal-title":"American Heart Journal"},{"issue":"16","key":"10.1002\/14651858.CD012058.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","article-title":"Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD012058.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.106.607994","article-title":"Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience","volume":"115","author":"Rajagopalan","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0042|cit42","unstructured":"AnGes MG Inc Report on long-term data of Collategene (HGF plasmid). Japanese Phase III study for CLI AnGes MG Inc 2010"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0043|cit43","unstructured":"Anon Academic release of data from phase III clinical trial of HGF gene therapy conducted in Japan https:\/\/www.anges.co.jp\/en\/index.php"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0044|cit44","unstructured":"Anon Announcement of results of phase III clinical trials of HGF gene therapy in Japan AnGes MG, Inc. 2007"},{"issue":"9","key":"10.1002\/14651858.CD012058.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/156720211796558050","article-title":"Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia","volume":"8","author":"Anghel","year":"2011","journal-title":"Current Neurovascular Research"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0047|cit47","first-page":"S20","article-title":"Hepatocyte growth factor gene therapy for patients with critical limb ischemia: results of a Phase I dose-escalation trial","volume":"73","author":"Biggs","year":"2009","journal-title":"Catheterization and Cardiovascular Interventions"},{"issue":"10","key":"10.1002\/14651858.CD012058.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1464-5491.2008.02557.x","article-title":"Skin permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product","volume":"25","author":"Leeuw","year":"2008","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012058.pub2-BIB0049|cit49","first-page":"49","article-title":"Combination of reconstructive vascular operations with gene-engineering technologies of angiogenesis stimulation: a present-day policy aimed at improving the remote results of treating patients with lower limb chronic ischaemia","volume":"14","author":"Gavrilenko","year":"2008","journal-title":"Angiologiia i Sosudistaia Khirurgiia\/Angiology & Vascular Surgery"},{"issue":"4","key":"10.1002\/14651858.CD012058.pub2-BIB0050|cit50","first-page":"29","article-title":"Results of comprehensive treatment of patients with chronic lower limb ischaemia using gene-engineering technologies of angiogenesis stimulation","volume":"21","author":"Gavrilenko","year":"2015","journal-title":"Angiology and Vascular Surgery"},{"issue":"12","key":"10.1002\/14651858.CD012058.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.RES.86.12.1198","article-title":"Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects","volume":"86","author":"Kalka","year":"2000","journal-title":"Circulation Research"},{"issue":"10","key":"10.1002\/14651858.CD012058.pub2-BIB0052|cit52","first-page":"OR067","article-title":"Differences in collateral-dependent muscle perfusion may explain efficacy variation in clinical angiogenic gene therapy","volume":"26","author":"Korpisalo","year":"2015","journal-title":"Human Gene Therapy"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0053|cit53","first-page":"S73","article-title":"Phase III comparison of intramuscular delivery of ANG1 (a vascular endothelial growth factor containing plasmid) with placebo in diabetic patients with critical limb ischaemia","volume":"3","author":"Kusumanto","year":"2001","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1002\/14651858.CD012058.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/hum.1998.9.10-1481","article-title":"Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia","volume":"9","author":"Laitinen","year":"1998","journal-title":"Human Gene Therapy"},{"issue":"18","key":"10.1002\/14651858.CD012058.pub2-BIB0055|cit55","first-page":"4063","article-title":"Catheter-mediated VEGF gene transfer to human lower limb arteries after PTA","volume":"100","author":"Makinen","year":"1999","journal-title":"Circulation"},{"issue":"7-8","key":"10.1002\/14651858.CD012058.pub2-BIB0056|cit56","first-page":"210","article-title":"Development of therapeutic angiogenesis gene therapy using HGF","volume":"16","author":"Morishita","year":"2014","journal-title":"Journal of Gene Medicine"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0057|cit57","unstructured":"NCT02016755 A phase IIB pilot study of a modified dosage regimen of AMG0001 in subjects with critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT02016755"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0058|cit58","unstructured":"NCT02544204 SDF1 plasmid treatment for patients with peripheral artery disease (STOP-PAD) clinicaltrials.gov\/ct2\/show\/NCT02544204"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0059|cit59","first-page":"302","article-title":"Protocol#0207-546: a phase I\/II, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of AMG0001 to improve perfusion in critical leg ischemia","volume":"14","author":"Powell","year":"2003","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0060|cit60","first-page":"770","article-title":"Assessment of safety and efficiency of intramuscular gene therapy with VEGF-2 in patients with critical limb ischaemia","volume":"100","author":"Rauh","year":"1999","journal-title":"Circulation"},{"issue":"e-Suppl A","key":"10.1002\/14651858.CD012058.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1097\/01.hjh.0000379835.51523.07","article-title":"Blood pressure response and higher count of circulating endothelial progenitors predict angiogenic gene therapy effectiveness in hypertensive patients with chronic limb ischemia","volume":"28","author":"Talitskiy","year":"2010","journal-title":"Journal of Hypertension"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD012058.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"E2069","DOI":"10.1016\/S0735-1097(12)62070-1","article-title":"Magnetic resonance imaging is useful for the estimation of therapeutic angiogenesis effect in patients with chronic limb ischemia","volume":"59","author":"Talitskiy","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0063|cit63","first-page":"1011","article-title":"Evaluation of angiogenic gene therapy effect with laser doppler flowmetry and magnetic resonance imaging in patients with chronic limb ischemia","volume":"33","author":"Talitskiy","year":"2012","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD012058.pub2-BIB0064|cit64","first-page":"A73","article-title":"The efficacy and safety of DVC1-0101 for intermittent claudication secondary to peripheral artery disease: study protocol of a randomized phase IIb trial","volume":"24","author":"Fujino","year":"2013","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0065|cit65","unstructured":"NCT00080392 EW-A-401 to treat intermittent claudication clinicaltrials.gov\/ct2\/show\/NCT00080392"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0066|cit66","unstructured":"NCT00304837 VEGF gene transfer for critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT00304837"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0067|cit67","unstructured":"NCT02144610 Efficacy and safety of AMG0001 in subjects with critical limb ischemia (AGILITY) clinicaltrials.gov\/show\/NCT02144610"},{"issue":"5302","key":"10.1002\/14651858.CD012058.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD012058.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012058.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e018184","DOI":"10.1136\/bmjopen-2017-018184","article-title":"Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK","volume":"8","author":"Cea-Soriano","year":"2018","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jvs.2009.09.044","article-title":"Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia","volume":"50","author":"Conte","year":"2009","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"De Haro J Acin F Lopez-Quintana A Florez A Martinez-Aguilar E Varela C Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease Heart and Vessels 2009 321 8","DOI":"10.1007\/s00380-008-1140-z"},{"issue":"9901","key":"10.1002\/14651858.CD012058.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD012058.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1742-1241.2008.01842.x","article-title":"Gene therapy as a novel therapeutic option in the treatment of peripheral vascular disease: systematic review and meta-analysis","volume":"62","author":"Ghosh","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD012058.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011741.pub2","article-title":"Growth factors for angiogenesis in peripheral arterial disease","author":"Gorenoi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1024\/0301-1526\/a000298","article-title":"Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials","volume":"42","author":"Hammer","year":"2013","journal-title":"VASA. Zeitschrift fur Gefasskrankheiten"},{"issue":"7414","key":"10.1002\/14651858.CD012058.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0078|cit78","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012058.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/ten.tec.2008.0323","article-title":"Comparison of viral and nonviral vectors for gene transfer to human endothelial progenitor cells","volume":"15","author":"Kealy","year":"2009","journal-title":"Tissue Engineering. Part C, Methods"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/mt.2011.18","article-title":"Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle","volume":"19","author":"Kuliszewski","year":"2011","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD012058.pub2-BIB0081|cit81","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012058.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/hgtb.2012.159","article-title":"Robust, efficient, and practical electrogene transfer method for human mesenchymal stem cells using square electric pulses","volume":"24","author":"Liew","year":"2013","journal-title":"Human Gene Therapy Methods"},{"issue":"9","key":"10.1002\/14651858.CD012058.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1185\/03007990802274379","article-title":"Management of peripheral arterial disease patients: comparing the ACC\/AHA and TASC-II guidelines","volume":"24","author":"Mohler","year":"2008","journal-title":"Current Medical Research and Opinion"},{"issue":"Suppl S","key":"10.1002\/14651858.CD012058.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"Journal of Vascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1677\/jme.0.0300331","article-title":"Tetracycline-regulated secretion of human insulin in a transfected non-endocrine cell line","volume":"30","author":"Scougall","year":"2003","journal-title":"Journal of Molecular Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD012058.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejvs.2011.04.030","article-title":"Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia","volume":"42","author":"Belle","year":"2011","journal-title":"European Journal of Vascular & Endovascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD012058.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012058","article-title":"Gene therapy for peripheral arterial disease","author":"Liew","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012058.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T09:03:08Z","timestamp":1651741388000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012058.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":87,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012058.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}